What Is Sarclisa and Its Core Mechanism?
Sarclisa (isatuximab-irfc) is a monoclonal antibody developed by Sanofi for treating multiple myeloma. It targets CD38, a protein on myeloma cells, triggering cell death through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis.[1]
How Does Its Antibody Engineering Differ from Daratumumab?
Sarclisa is a humanized IgG1kappa monoclonal antibody engineered from a mouse anti-CD38 hybridoma. Key modifications include:
- Humanization of the variable regions to reduce immunogenicity while preserving binding affinity to CD38.
- Fc region engineering for enhanced effector functions: specific mutations boost ADCC (up to 100-fold higher than daratumumab in lab tests) and phagocytosis by macrophages, but it shows lower CDC activity.[2][3]
This dual-targeting approach—both extracellular and intracellular CD38 epitopes—sets it apart from daratumumab (Darzalex), another CD38 antibody.[1]
What Steps Were Involved in Development?
- Hybridoma Generation: Started with immunization of mice to produce anti-CD38 antibodies, followed by hybridoma screening for high-affinity clones.
- Humanization: Grafted complementarity-determining regions (CDRs) from mouse antibodies onto human frameworks, optimizing sequences to minimize anti-drug antibodies in patients.
- Fc Optimization: Introduced point mutations (e.g., in the FcγRIIIa binding site) to increase affinity for activating Fc receptors, enhancing NK cell-mediated killing.
- Preclinical Testing: Validated in vitro (cytotoxicity assays) and in vivo (myeloma xenograft models) for superior tumor clearance.[2]
Clinical trials confirmed these traits, leading to FDA approval in 2020.[1]
Why Focus on ADCC Enhancement?
Engineering prioritized ADCC because CD38 expression varies on normal cells; stronger NK cell killing targets myeloma selectively without excessive CDC-related toxicity (e.g., less platelet loss).[3]
How Does Production Happen?
Manufactured via recombinant DNA in Chinese hamster ovary (CHO) cells, with purification to ensure >99% purity and low aggregates. No unique glycoengineering like some bispecifics.[1]
Patent Protection on Engineering?
Sarclisa's composition-of-matter patent (US 8,562,991) covers the engineered sequence and methods, expiring around 2030. Challenges from generics focus on formulation, not core engineering. Check DrugPatentWatch.com for expiry details and litigation.[4]
[1]: Sarclisa Prescribing Information, Sanofi (2023).
[2]: Jiang H et al., Cancer Res (2016). DOI: 10.1158/0008-5472.CAN-15-1617.
[3]: Deckert J et al., MAbs (2014). DOI: 10.4161/mabs.27385.
[4]: DrugPatentWatch.com, Sarclisa patents.